These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12467944)

  • 21. Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.
    Sharma T; Hughes C; Soni W; Kumari V
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):398-403. PubMed ID: 12845415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
    Alfaro CL; Wudarsky M; Nicolson R; Gochman P; Sporn A; Lenane M; Rapoport JL
    J Child Adolesc Psychopharmacol; 2002; 12(2):83-91. PubMed ID: 12188977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.
    Martin S; Lĵo H; Peuskens J; Thirumalai S; Giudicelli A; Fleurot O; Rein W;
    Curr Med Res Opin; 2002; 18(6):355-62. PubMed ID: 12442883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influence of serotonergic transmission on response to olanzapine].
    Mata-Pastor I; Arranz-Calderón MJ; Beperet-Urmeneta M; Pérez-Nievas F; Sham P; Kerwin R
    Actas Esp Psiquiatr; 2002; 30(5):265-71. PubMed ID: 12372221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.
    Dossenbach MRK ; Beuzen JN; Avnon M; Belmaker RH; Elizur A; Mark M; Munitz H; Schneidman M; Shoshani D; Kratky P; Grundy SL; Tollefson GD
    Clin Ther; 2000 Sep; 22(9):1021-34. PubMed ID: 11048902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-HT3 receptor antagonism by ondansetron does not attenuate prolactin response to d-fenfluramine challenge in healthy human subjects.
    Coccaro EF; Kavoussi RJ; Cooper TB; Hauger R
    Psychopharmacology (Berl); 1996 Sep; 127(2):108-12. PubMed ID: 8888375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.
    Henderson DC; Nasrallah RA; Goff DC
    J Clin Psychiatry; 1998 Nov; 59(11):585-8. PubMed ID: 9862604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Atypical neuroleptics in child- and adolescent psychiatry].
    Remschmidt H; Hennighausen K; Clement HW; Heiser P; Schulz E
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):45-57. PubMed ID: 10746298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focus on olanzapine.
    Green B
    Curr Med Res Opin; 1999; 15(2):79-85. PubMed ID: 10494490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tc-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients.
    Gonul AS; Kula M; Sofuoglu S; Tutus A; Esel E
    Eur Arch Psychiatry Clin Neurosci; 2003 Feb; 253(1):29-33. PubMed ID: 12664310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
    Baker RW; Ames D; Umbricht DS; Chengappa KN; Schooler NR
    Psychopharmacol Bull; 1996; 32(1):89-93. PubMed ID: 8927681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical efficacy of olanzapine].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):101-10. PubMed ID: 10495984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.
    Scheepers FE; Gispen-de Wied CC; Westenberg HG; Kahn RS
    Neuropsychopharmacology; 2001 Oct; 25(4):468-75. PubMed ID: 11557160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.